ShareValue scores for PRIM.JK: Valuation 55, Quality 30, Growth 47, Health 51.

PRIM.JK
IDX

Royal Prima PT

IDR 81.00(-2.41%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

5% to 17%
Valuation
55
Fair Value
Price vs Value
Quality
30
Weak
Business Strength
Growth
47
Moderate
Revenue & Earnings
Health
51
Moderate
Financial Stability
Momentum
47
Neutral
Price Trend

Company Details

About

PT Royal Prima Tbk engages in providing hospital services and drugs in Indonesia. The company operates its hospitals under the Royal Prima Medan, Royal Prima Jambi, and RSU Royal Prima Marelan names. The company also provides health services, such as inpatient and outpatient medical services, including specialist and sub-specialist care. In addition, the company offers orthopaedic, eye, neurology, internal medicine, obstetrics and gynaecology, heart, lung, Ent-kl, urology. Further, it provides other services, including general surgery, surgical oncology, plastic surgery, pediatric surgery, neurosurgery, digestive surgery, dermatologist and venereologist, psychiatric, dental polyclinic, oral surgery, vascular surgery, kidney and hypertension, endocrine metabolic diabetes. The company was founded in 2013 and is based in Jakarta, Indonesia.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026